First Databank (FDB) Releases New, Expanded Medication Decision Support Solutions at HIMSS13 Conference
FDB solutions support interoperability for Meaningful Use Stages 1 & 2, address alert fatigue and provide support for controlled substances prescribing
First Databank (FDB), a leading provider of clinical drug knowledge that improves medication-related decisions and patient outcomes, today announced new and expanded solutions that help address Meaningful Use Stages 1 and 2 interoperability criteria and enhance medication decision support. FDB drug knowledge experts will be demonstrating these solutions at the HIMSS13 Conference, March 3 – 7, in New Orleans, LA at the FDB booth, number 4241.
The FDB Interoperability Module™ now offers a full range of interoperable cross references between FDB clinical drug knowledge and standardized medication vocabularies designed to support the portability of patient medication, immunization, and allergy history between disparate health information systems. For instance, one recent enhancement provides RxNorm® mappings to FDB clinical screening content, enabling clinicians to utilize externally reported lists of RxNorm-based medication concepts in clinical screening, medication reconciliation, clinical quality measure calculations, and advanced decision support.
To guide developers in maximizing the use of FDB drug knowledge in meeting the interoperability requirements for Meaningful Use, FDB has developed a Meaningful Use for Medications Tip Sheet. To learn more, conference visitors are encouraged to stop by booth 4241 to meet with FDB data experts. Alternatively, the Tip Sheet is also available for download at www.fdbhealth.com/MU2
FDB will also be showcasing its latest version of AlertSpace® which addresses the challenging industry problem of “alert fatigue” in computerized provider order entry (CPOE) and other HIT systems. FDB has released new AlertSpace functionality allowing users to customize dose checking information, including dosing ranges, frequencies, units of measure and more. The ability to customize dose checking information is in addition to current functionality including customization of drug-drug and drug-allergy detection, visibility into common customizations and collaboration features.
As part of the AlertSpace demonstration, FDB will be previewing the ONC drug-drug interaction (DDIs) subset, which will soon be incorporated into AlertSpace. This will enable users to identify a subset of high-priority alerts to activate and a set of lower-priority alerts that can be filtered.
Denise Apcar, 650-872-4514
All Rights Reserved.